Breaking News
March 23, 2019 - Excess hormones could cause a condition that can lead to blindness in women, study finds
March 23, 2019 - Dramatic shifts in first-time opioid prescriptions bring hope, concern
March 23, 2019 - Antidepressant drugs may not work when neurons are out of shape
March 23, 2019 - TTUHSC El Paso to establish endowed chair in neurology through a major grant
March 23, 2019 - New device approved by FDA for treating patients with moderate-to-severe heart failure
March 23, 2019 - People with peripheral artery disease have lower Omega-3 Index, shows research
March 23, 2019 - Trigger warnings have minimal impact on how people respond to content, shows research
March 23, 2019 - Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies
March 23, 2019 - Selfish genetic elements amplify inflammation and age-related diseases
March 23, 2019 - Study provides new understanding of how the brain recovers from damage caused by stroke
March 23, 2019 - CRISPR/Cas libraries could revolutionize drug discovery
March 23, 2019 - Allergic reaction during pregnancy may alter sexual-development in offspring’s brain
March 23, 2019 - Seeing through a robot’s eyes helps those with profound motor impairments
March 23, 2019 - Recent research shows that ease of breastfeeding after C-section differs culturally
March 23, 2019 - Newly discovered parameters offer more control over efficient release of drugs
March 23, 2019 - ‘De-tabooing’ of abortion- Women would like more support from health care community
March 23, 2019 - Anti-TB drugs can increase susceptibility to Mtb reinfection
March 23, 2019 - New survey indicates need of attention to neglected tropical diseases
March 23, 2019 - Innovative in vitro method to develop easy-to-swallow medicine for children and older people
March 23, 2019 - Sugary drinks could raise risk of early deaths finds study
March 23, 2019 - Lian wins ENGINE grant for stem-cell-based therapy to treat Type 1 diabetes
March 23, 2019 - Overall, Physicians Are Happy and Enjoy Their Lives
March 23, 2019 - Researchers discover how blood vessels protect the brain during inflammation
March 23, 2019 - CDC study shows modest improvement in optimal hospital breastfeeding policy
March 23, 2019 - Family-based prevention program to reduce alcohol use among older teens
March 23, 2019 - Remote monitoring of implanted defibrillators in heart failure patients prevents hospitalizations
March 23, 2019 - Appropriate doffing of personal protective equipment may reduce healthcare worker contamination
March 23, 2019 - Window screens can suppress mosquito populations, reduce malaria in Tanzania
March 23, 2019 - Researchers discover new biomarker for postoperative liver dysfunction
March 23, 2019 - Pregnancy history may be linked to cognitive function in older women, finds study
March 23, 2019 - Study shows ticagrelor is equally safe and effective as clopidogrel after heart attack
March 23, 2019 - FDA Approves First Drug for Postpartum Depression, Zulresso (brexanolone)
March 23, 2019 - New guidelines outline new treatment management for psoriasis
March 23, 2019 - Thermally abused cooking oil may promote progression of breast cancer
March 23, 2019 - High-fructose corn syrup fuels growth of colon tumors in mice
March 23, 2019 - Partnership aims at establishing best practices to promote diversity in clinical trials
March 23, 2019 - New study examines presence of microbes in tap water from residences, office buildings
March 23, 2019 - Early life trauma may affect brain structure, contribute to major depressive disorder
March 23, 2019 - NIH starts clinical trial of drug to treat cravings associated with opioid use disorder
March 23, 2019 - Cervix bacteria, immune factors could be a warning signal of premature birth, reports new research
March 23, 2019 - Worst-ever emergency care performance figures underscore the need to focus on staffing
March 23, 2019 - The Current issue of “The view from here” is concerned with Cancer
March 23, 2019 - Mouse model validates how ‘good’ and ‘bad’ bacteria affect acne
March 23, 2019 - Individual amygdala neurons respond to touch, imagery and sounds
March 23, 2019 - Combination of two topical creams can prevent cancer
March 23, 2019 - Study suggests depression screening when assessing African-Americans for schizophrenia
March 23, 2019 - New electronic support system for choosing drug treatment based on patient’s genotype
March 23, 2019 - First-of-its-kind study provides pregnancy statistics of imprisoned U.S. women
March 23, 2019 - Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
March 23, 2019 - Laparoscopy: MedlinePlus Lab Test Information
March 23, 2019 - Shellfish allergies: can they be treated?
March 23, 2019 - Toilet seat heart monitoring system
March 23, 2019 - Researchers identify way to improve common treatment for PTSD
March 23, 2019 - High potency cannabis use linked to psychosis finds study
March 23, 2019 - Evoke Pharma Submits Response to FDA Review Letter for Gimoti NDA
March 23, 2019 - Tracking HIV’s ever-evolving genome in effort to prioritize public health resources
March 23, 2019 - Scientists grow most sophisticated brain organoid to date
March 23, 2019 - ADHD drug raising risk of psychosis
March 22, 2019 - FDA approves brexanolone, first drug developed to treat postpartum depression
March 22, 2019 - Gruesome cat and dog experiments by the USDA exposed
March 22, 2019 - Ball pits used in children’s physical therapy may contribute to germ transmission
March 22, 2019 - Long-term use of inexpensive weight-loss drug may be safe and effective
March 22, 2019 - FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
March 22, 2019 - Anti-Müllerian Hormone Test: MedlinePlus Lab Test Information
March 22, 2019 - Finding the right exercise, diet aids for HIV patients
March 22, 2019 - Health Plans For State Employees Use Medicare’s Hammer On Hospital Bills
March 22, 2019 - Researchers develop new tool for imaging large groups of neurons in living animals
March 22, 2019 - Certain bacteria and immune factors in vagina may cause or protect against preterm birth
March 22, 2019 - Research identifies guidelines for prioritizing hepatitis C treatment in U.S. prisons
March 22, 2019 - Novel breath test could pave new way to non-invasively measure gut health
March 22, 2019 - Pharmaceutical and personal care products may result in new contaminants in waterways
March 22, 2019 - New model could revolutionize the way researchers investigate spread of pathogens
March 22, 2019 - MSU professor receives NSF CAREER grant for biosensor diagnostics
March 22, 2019 - High-fat, high-sugar diet in mouse mothers causes problems in the hearts of offspring
March 22, 2019 - ACC: Catheter Ablation Does Not Cut Mortality, Stroke in A-Fib
March 22, 2019 - Wiedemann-Rautenstrauch syndrome – Genetics Home Reference
March 22, 2019 - Health insurance is not assurance of healthcare
March 22, 2019 - Supporting “curiosity-driven research” at the Discovery Innovation Awards
March 22, 2019 - Must-Reads Of The Week (Some Flying Below The Radar)
March 22, 2019 - Newly engineered nanoscale protein micelles can be tracked by MRI
Success for new cholesterol-lowering drug

Success for new cholesterol-lowering drug

image_pdfDownload PDFimage_print

A new, oral drug that effectively lowers cholesterol looks set for clinical approval. The latest trials of the drug have shown that it is safe when used in conjunction with widely prescribed statins.

cholesterol builds up in the walls of arteriesVictor Josan | Shutterstock

The new study, published in The New England Journal of Medicine, was the largest study to date to test the efficacy of bempedoic acid, which is yet to be approved in Europe.

The oral medication impedes the body’s ability to create cholesterol, and could be taken in conjunction with patients’ existing statins treatments, as well acting as a treatment for those unable to take statins due to adverse side effects or interactions with other medications.

Low-density lipoprotein (LDL) cholesterol, often dubbed “bad” cholesterol, is responsible for carrying cholesterol to cells. An excess of LDL accumulates on artery walls, restricting blood flow to the heart, brain, and the rest of the body.

This can lead to a number of serious health problems including atherosclerosis, coronary heart disease, heart attack, stroke, and peripheral arterial disease, and can also increase the risk of blood clots throughout the body.

We know that reducing your cholesterol levels is key to cutting the risk of heart attack and stroke, particularly if you already have established heart disease.

Our latest study shows that bempedoic acid could be another addition to the arsenal of cholesterol-lowering treatments available to patients.

What we have is a new class of drug that could be given to patients who are already taking statins and could help them to further reduce their cholesterol levels and thus potentially cut their risk of heart attacks and strokes.”

Professor Kausik Ray, Lead Author

Statins are routinely prescribed to help to lower cholesterol in patients who are at high risk of complications caused by high cholesterol, including those with diabetes, hereditary conditions, and patients who have had a previous heart attack or stroke.

Although bempedoic acid works in a similar way to statins by blocking a cholesterol-producing enzyme ATP-citrate lyase, it boasts some advantages over commonly used statins.

“One of the key advantages of bempedoic acid is supposed to be that it shouldn’t cause the muscle side effects reported by some statins users, as it is taken up by the liver and needs to be converted into its active form via an enzyme only found in the liver,” Ray elucidates.

The study involved 2230 patients, 1488 of whom were given bempedoic acid and 742 a placebo. The patients came from a range of countries, from the UK and Germany to Poland, Canada, and the US.

Along with patients on varying intensities of cholesterol-lowering treatments, patients with familial hypercholesterolemia were also included. Hypercholesterolemia is a hereditary condition that results in increased cholesterol levels and consequent elevated risk of cardiovascular diseases and strokes.

During the 52-week trial, bempedoic acid added to “maximally tolerated statin therapy did not lead to a high incidence of overall adverse events […] and led to significantly lower LDL cholesterol levels.”

After three months, bempedoic acid had reduced LDL cholesterol levels by an average of 18.1% when compared with the placebo group. The intensity of the patients’ existing treatment plans did not affect the efficacy of bempedoic acid.

However, incidence rates of gout within the test group did see a small increase due to slightly higher levels of uric acid in the blood. Incidence of serious health conditions was not reported in either group.

A second study published by The New England Journal of Medicine used data from 654,783 people to investigate the long-term effects of bempedoic acid.

The study tracked genetic markers to determine the potential effects of inhibiting the ATP-citrate lyase enzyme with bempedoic acid. It was then compared with the enzyme that statins usually inhibit, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR).

The study concluded that its results “strongly [imply] that inhibiting ATP-citrate lyase reduces plasma LDL cholesterol levels in the same way that inhibiting HMGCR with a statin reduces LDL cholesterol levels.”

Bempedoic acid was deemed to be potentially equally safe and effective as statins, and that it could also avoid some of the negative muscle-related side effects experienced with statins, as the new medication operates through a different mechanism of action.

“Once converted to the active form [bempedoic acid] cannot leave the liver, so it can’t enter muscles and hence could be of considerable advantage for some,” Ray explains.

Overall, these latest studies show that not only is the treatment generally well-tolerated being comparable with placebo, and potentially safe over longer periods, but that when added to high intensity statin treatment it can help to further reduce LDL cholesterol levels.

The ongoing trial, called ‘CLEAR OUTCOMES’, is specially testing even longer-term safety and whether this approach reduces cardiovascular disease in addition to lowering cholesterol.”

Professor Kausik Ray, Lead Author

Esperion, the US pharmaceutical company that is behind the new drug, is working towards gaining a license to sell the drug in both Europe and the US in 2019. However, there is no certainty that bempedoic acid would be available for patients worldwide within this timeframe.


Mendelian Randomization Study of ACLY and Cardiovascular Disease. NEJM. 14th March 2019.

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. NEJM. 14th March 2019.

Tagged with:

About author

Related Articles